Table 2.
Response | Arm A (azacitidine + durvalumab) (n = 42) | Arm B (azacitidine) (n = 42) | P | ||
---|---|---|---|---|---|
No. (%) | 95% CI | No. (%) | 95% CI | ||
ORR (CR + PR + mCR + HI) | 26 (61.9) | 47.22-76.59 | 20 (47.6) | 32.51-62.72 | .1838 |
CR | 3 (7.1) | 0.00-14.93 | 4 (9.5) | 0.65-18.40 | |
mCR | 15 (35.7) | 21.22-50.21 | 8 (19.0) | 7.17-30.92 | |
PR | 0 | 0 | |||
HI only | 8 (19.0) | 7.17-30.92 | 8 (19.0) | 7.17-30.92 | |
SD | 6 (14.3) | 3 (7.1) |
ITT, intent to treat; PR, partial remission; SD, stable disease.